BioSpace News Archive

Ondine Biomedical (OBI:LON), a Canadian life sciences company, reported that photodisinfection being developed for food processing demonstrated high efficacy against key food-borne pathogens.

This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases.

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).

BioVie Inc. today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry Annual Meeting.

Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of novel mRNA-based cancer therapeutics that utilizes Samyang’s proprietary drug delivery technology.

TPG (NASDAQ: TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE: ABC) today announced that they have agreed to acquire OneOncology, a network of leading oncology practices, from General Atlantic, a leading global growth equity firm.

Edesa Biotech, Inc. announced today that the company will join a Canadian delegation of officials and industry participating in Swiss Biotech Day on April 24-25, 2023 in Basel, Switzerland.

Xcelerate, Inc. (OTCQB:XCRT) announced today it filed two utility patent applications under application numbers 18/187,352 and 18/189,441.

Schrödinger will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET to provide a business update and report first quarter 2023 financial results.